Running HIV treatment and chemotherapy together
Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Treating lymphoma in someone with HIV means running two demanding treatments at once, and the interactions between them are specific and consequential rather than theoretical.
Most of this is handled by the oncology and HIV teams together. It is worth understanding anyway, because the key decisions are made in the first days and patients are often the only person in the room who knows every medicine they take.
Related pages: AIDS-related lymphoma
The bottom line
- Antiretroviral therapy is continued through chemotherapy rather than stopped.
- Boosted regimens raise chemotherapy drug levels through the same liver enzyme.
- Rituximab can reactivate hepatitis B, which requires screening beforehand.
- Zidovudine is avoided during chemotherapy because it suppresses the marrow.
- The best antiretroviral regimen during chemotherapy, where practice is consistent but trial evidence is thin.
- How much interaction-driven toxicity still occurs in practice, which is likely underestimated.
The story, step by step
What the evidence labels mean
Why ART is not paused
What happens
The first principle.
What the research shows
- Antiretroviral therapy continues through chemotherapy. Stopping it allows the virus to rebound and the CD4 count to fall at exactly the moment the immune system is under most strain.
- Outcomes for HIV-associated lymphoma now approach those of people without HIV, and continuous antiretroviral therapy is a large part of why.
- The CD4 count will fall during chemotherapy regardless. That is expected, is managed with prophylaxis, and recovers afterwards.
- Viral load and CD4 are monitored through treatment, and a rising viral load usually means doses are being missed rather than that the regimen has failed.
- Nausea and mucositis make taking tablets hard. Say so rather than skipping doses; anti-sickness treatment, timing changes or a different formulation usually solve it.
Why it matters
The old practice of interrupting HIV treatment during chemotherapy has been abandoned, and knowing that helps when a non-specialist suggests it.
What's still uncertain
- Optimal monitoring frequency during chemotherapy, which varies by centre.
Read more
- National Cancer Institute: AIDS-related lymphoma treatment (PDQ)Government
- HHS: Clinical guidelines for antiretroviral therapy in adults and adolescentsGovernment
- CDC: HIV and cancerGovernment
Next: The switch
Why the regimen often changes first
What happens
The interaction that matters most.
What the research shows
- Ritonavir and cobicistat, the boosters used with some antiretrovirals, strongly inhibit the liver enzyme CYP3A4.
- Several chemotherapy drugs are cleared by that same enzyme, including vincristine, doxorubicin, etoposide and cyclophosphamide. Blocking it raises their levels substantially.
- With vincristine this is serious: elevated levels cause severe peripheral neuropathy and, rarely, worse. Cases of significant harm from this combination are well documented.
- Standard practice is therefore to switch to an unboosted regimen, usually built around an integrase inhibitor such as dolutegravir or raltegravir, before chemotherapy begins.
- Zidovudine is avoided during chemotherapy because it suppresses the bone marrow on top of the chemotherapy's own effect.
- Some non-nucleoside drugs induce the same enzyme and lower chemotherapy levels instead, which risks under-treating the lymphoma.
- An HIV pharmacist or specialist reviews the whole list before cycle one. If nobody has mentioned changing your regimen, ask whether it has been checked.
Why it matters
This is the single most important technical point in the dual management of HIV and lymphoma, and it is usually invisible to the patient.
What's still uncertain
- How much residual interaction risk remains with modern unboosted regimens, which is low but not zero.
Read more
- HHS: HIV drug-drug interaction guidanceGovernment
- National Cancer Institute: AIDS-related lymphoma treatment (PDQ)Government
- HHS: Clinical guidelines for antiretroviral therapy in adults and adolescentsGovernment
Next: Hepatitis B
The check before rituximab
What happens
A safety step with a narrow window.
What the research shows
- Rituximab depletes B-cells, which can allow hepatitis B to reactivate in anyone who has ever been infected, including people whose infection appeared resolved years ago.
- Reactivation can cause severe, sometimes fatal, liver failure, and it is preventable.
- Everyone should be screened before rituximab: hepatitis B surface antigen and core antibody, not surface antibody alone.
- Where either is positive, antiviral prophylaxis, usually tenofovir or entecavir, is given through treatment and for a period afterwards.
- This matters more in HIV than in the general population, because hepatitis B co-infection is far more common.
- Hepatitis C is also checked. It is now curable in most people and is treated, though usually after lymphoma treatment rather than during.
- Many antiretroviral regimens already contain tenofovir, which treats hepatitis B. That is a reason not to stop or switch away from it without the liver being considered.
Why it matters
If you have ever had hepatitis B, make sure the oncology team knows before rituximab, not after.
What's still uncertain
- Optimal duration of antiviral prophylaxis after rituximab, which differs between guidelines.
Read more
- MedlinePlus: Hepatitis BGovernment
- National Cancer Institute: AIDS-related lymphoma treatment (PDQ)Government
- HHS: Guidelines for opportunistic infections in adults and adolescents with HIVGovernment
Next: Support
Prophylaxis, growth factors and tumour lysis
What happens
What runs alongside the chemotherapy.
What the research shows
- Prophylaxis against Pneumocystis pneumonia is standard, usually with co-trimoxazole, and continues until CD4 counts recover after treatment.
- Antifungal and antiviral prophylaxis, and prophylaxis against Mycobacterium avium complex at very low CD4 counts, are added depending on the situation.
- Granulocyte colony-stimulating factor, such as filgrastim, is used routinely with these regimens to shorten the period of very low neutrophils.
- Tumour lysis syndrome is a particular risk in Burkitt lymphoma, which divides extremely quickly. Fluids and allopurinol or rasburicase are given before and during the first cycle, with close monitoring of potassium, phosphate and uric acid.
- Central nervous system prophylaxis, usually chemotherapy injected into the spinal fluid, is given in Burkitt lymphoma and in higher-risk large B-cell lymphoma, because these cancers can seed the brain and spinal fluid where most drugs do not reach.
- Dose-adjusted EPOCH with rituximab is commonly used for HIV-associated large B-cell lymphoma, and the older concern about rituximab at very low CD4 counts is handled by the team rather than being a reason to withhold it.
- Autologous stem cell transplant and, increasingly, CAR-T therapy are used in people with HIV whose lymphoma relapses, and HIV status alone is no longer a barrier to either.
Why it matters
The supportive package around the chemotherapy is as carefully planned as the chemotherapy itself, and it is why these regimens are now deliverable at full dose.
What's still uncertain
- How far CAR-T outcomes in people with HIV match those without, where early data are encouraging and numbers are small.